A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

This study is being done to answer the following question: Can we extend your life by adding the immunotherapy drug atezolizumab to the usual radiation treatment? We are doing this study because we want to find out if this approach is better or worse than the usual approach for inoperable, early stage non-small cell lung cancer. The usual approach is defined as care that most people get for inoperable, early stage non-small cell lung cancer (NSCLC). The usual approach for patients who are not in a study is treatment with radiation alone. The use of radiation for early stage NSCLC is not regulated by the FDA.

Are you Eligible? (Inclusion Criteria)

• Are you 18 years of age or older? Have you been diagnosed with inoperable, early stage non-small cell lung cancer, and have not yet undergone treatment for it? Are you able to make regularly scheduled visits to the clinic for treatment and examinations?